MedBright AI Announces the Appointment of Christopher Heath as CEO and Termination of Letter of Intent


VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the "Company" or "MedBright AI") (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) is pleased to announce that Christopher Heath has joined MedBright AI as Chief Executive Officer effective August 9, 2024.

Mr. Heath previously served as Chief Executive Officer at Convalo Health Corp., a publicly traded network of drug and alcohol inpatient and outpatient clinics that generated gross revenues of eight figures annually. Since Convalo, Mr. Heath has invested in and consulted for companies in the medical and technology spaces, helping to lead both startups and mature businesses forward in innovative ways. Mr. Heath has over a decade of experience in the public capital markets which has provided him with a comprehensive understanding of industry dynamics and financial strategies.

"Mr. Heath's combination of experience in leading a network of mental health clinics and his involvement in the medical and technology ecosystems aligns seamlessly with MedBright's mission of investing in companies that are using AI-enabled tools to improve patient outcomes while positively impacting medical practices' bottom lines," said Jaime Gerber, Chairman of MedBright AI. "Over the past decade, Mr. Heath has consistently demonstrated his ability to successfully lead and guide companies in a way that optimizes shareholder value."

Mr. Heath adds, "I’m excited to join the MedBright AI Investments leadership team at the start of what we believe will be an AI-led revolution in the healthcare sector. I look forward to leveraging my experience to drive innovation and growth in this burgeoning field."

The Company also announces that it has decided to terminate the letter of intent previously announced by the Company on June 20, 2024 regarding the proposed acquisition of the Company by Numinus Wellness Inc.

About MedBright AI Investments Inc.

MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright seeks to leverage the diverse background and skillsets of its management group and advisors, which include professionals from a variety of disciplines, including physicians and professors from Yale University Hospital, artificial intelligence specialists, and healthcare industry finance and management specialists, in order to identify and structure the Company’s investments.

For further information, please contact:

MedBright AI Investments Inc.
Mr. Chris Heath, Chief Executive Officer
Email: investors@medbright.ai
Phone: (604) 602-0001
www.medbright.ai

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: management’s beliefs regarding the alignment of Mr. Heath’s experience in leading a network of mental health clinics and his deep involvement in the MedTech ecosystem and the Company’s mission; and management’s beliefs regarding AI’s role in the healthcare sector, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: Mr. Heath’s experience will align with the Company’s mission; and the anticipated prominence of AI in the future healthcare sector. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: Mr. Heath’s experience will not align with the Company’s mission; and AI may not have as significant a role in the future healthcare sector as the Company anticipates.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.